Abstract
METHODS:
Proteomic profiling of plasma was conducted in CVD patients receiving apabetalone in the 3 month (ASSERT) and 6 month (SUSTAIN & ASSURE) phase 2 trials, as well as in patients with stage 4/5 CKD receiving a single dose in a phase 1 pharmacokinetic study. Human coronary artery vascular smooth muscle cells (CAVSMCs) were used to assess expression of VC markers, transdifferentiation in osteogenic conditions, and extracellular mineralization that leads to pathology. ChIP-seq examined BRD4 assembly on chromatin during osteogenic transdifferentiation and the effects of apabetalone.
RESULTS:
Apabetalone reduced circulating levels of proteins associated with VC in phase 2 trials in CVD patients including osteopontin, osteoprotegerin, & alkaline phosphatase (ALP). Proteomic assessment of plasma from CKD patients vs matched controls demonstrated activation of molecular pathways driving VC including BMP-2 signaling and RANK signaling in osteoclasts. Both pathways were downregulated by apabetalone 12 hours post dose in the CKD cohort. Mechanistic effects of apabetalone were examined in vitro. Transdifferentiation of CAVSMCs with osteogenic conditions induced expression of ALP, RUNX2, MGP, & WNT5A, which was suppressed by apabetalone. Further, apabetalone dose dependently countered extracellular calcium deposition. Compared to basal conditions, transdifferentiation to a calcifying phenotype promoted re-distribution of BRD4 on chromatin, resulting in fewer enhancers (118 in osteogenic, 288 in basal). 38 unique enhancers were generated in osteogenic conditions, several of which were in proximity to genes associated with calcification or atherosclerosis. Apabetalone dose dependently reduced levels of BRD4 on many of these enhancers, which correlated with decreased expression of the associated gene. Genome wide, apabetalone decreased the size of BRD4 containing enhancers, consistent with its mechanism of action. • Apabetalone reduced expression of markers of transdifferentiation & genes that promote calcification of CAVSMCs.
Apabetalone suppresses extracellular calcium deposition in human
• Apabetalone reduced the number and size of BRD4-rich enhancers, consistent with displacement of BRD4 from chromatin.
• BRD4 ChIP-seq identified 38 unique genes associated with CAVSMC transdifferentiation and calcification.
• Involvement of BRD4 in CAVSMC transdifferentiation & calcification is a novel discovery.
• The impact of apabetalone on biomarkers, renal function, and CVD outcomes in patients with impaired kidney function is being evaluated in the phase 3 BETonMACE trial. z-score negative = downregulation ; z-score positive = upregulation no modulation of either pathway by apabetalone in control subjects.
Summary and Conclusions
Method: CAVSMCs were cultured for 12 days in basal or osteogenic conditions ± apabetalone or comparator BET inhibitor JQ1. BRD4 ChIP-seq identified the number, genomic location, and size of BRD4-rich enhancers.
BET proteins, such as BRD4, bind acetylated lysine (ac) on histones or transcription factors (TF) via bromodomains (BD), and recruit transcriptional machinery to drive expression of BET sensitive genes. Apabetalone targets bromodomains in BET proteins, causing release from chromatin and downregulation of BET sensitive gene expression. 
